obesity drug news today glp-1 2025 Dozens of new drugs are coming: these are the ones to watch Outlook for obesity in 2025:

Description

Expect 1015% on orforglipron, 1415% on injectable semaglutide, and 1820% on tirzepatide if you take the drug consistently at target dose with lifestyle support

Ozempic is available in 0.5 mg, 1 mg, and 2 mg dosages, while Mounjaro is available in 2 mg, 12.5 mg, and 15 mg dosages

doi: 10.1111/dom.14507 116 WildingJPHBatterhamRLCalannaSDaviesMVan GaalLFLingvayIet al

If the phase 2b trial goes well, its possible the company could trial the combination of bimagrumab and tirzepatide or another one of the GLP-1 agonists in its pipeline

In 2025, insurance coverage became increasingly restrictive: The rollbacks were happening everywhere at once: Independence Blue Cross stopped covering GLP-1s for weight loss